← 홈

Antibody · 림프종

169개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 169개
AntibodystaleRochePhase 2

rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin (rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim (rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim)

Large B Cell Lymphoma · Large B Cell Lymphoma

#LargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

rituximab, ifosfamide, carboplatin, and etoposide phosphate (rituximab, ifosfamide, carboplatin, and etoposide phosphate)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePreclinical

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePreclinical

tislelizumab, etoposide, pegaspargase (tislelizumab, etoposide, pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleGlaxoSmithKlinePhase 2

tositumomab (tositumomab)

Lymphoma, B-Cell · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleBeth ChristianPhase 2

veltuzumab (veltuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 24%임상시험 1상태 ACTIVE
AntibodystaleBeth ChristianPhase 2

veltuzumab and milatuzumab (veltuzumab and milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 24%임상시험 1상태 ACTIVE
AntibodystaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED

9 / 9 페이지

← 이전다음 →